A new rapid turnaround genetic test for spinal muscular atrophy, found to reduce time to results from 21 days to 4 days, will be offered at no charge to qualified individuals in the United States as part of the SMA Identified program.
Evidence-based therapies are available for the acute symptomatic treatment of migraine in children and adolescents, but evidence is lacking for the impact of many treatments for migraine prevention.
The brief, parent-report Psychosocial Assessment Tool 2.0_General questionnaire may be effective for screening psychosocial risks in children and adolescents with recurrent headache.
“We found that vitamin D supplementation may alleviate ADHD symptoms, which were supported by improvements in ADHD total scores, inattention scores, hyperactivity scores, and behavior scores,” the authors stated.
The incidence of neonatal abstinence syndrome has steadily and notably increased in Canada and researchers believe this increase highlights the importance of implementing integrated care for the mother-infant dyad during and after the birth process.
Less pronounced clinical and radiologic features in asymptomatic idiopathic intracranial hypertension (IIH) may serve as early indicators for symptomatic IIH in children.
According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.
Although the long-term effects of melatonin in school-aged children are unknown, its use is common in this population, according to the findings of a recently published cross-sectional study.
Its extremely high price tag means that a lifesaving medication to treat young children with spinal muscular atrophy is simply too expensive for most families.
